European operations to support clinical development of AS‑241 and expanded collaboration across the EU, the Middle East, and the Gulf States
PASADENA, Calif., April 16, 2026 – AcuraStem, a patient‑based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced the establishment of its European subsidiary, AcuraStem P2 Ltd, based in Nicosia, Cyprus.
The new entity will support AcuraStem’s expanding international operations as the company advances its lead clinical candidate, AS‑241, toward first‑in‑human testing. AcuraStem has built strong relationships with leading European ALS research institutions and clinical investigators, and the establishment of AcuraStem P2 Ltd provides a formal operational base to deepen collaboration with partners across the European Union, engage with EU regulatory bodies and funding programs, and support future clinical development activities.
In addition to its strategic position within the European Union, Cyprus sits at a crossroads between Europe, the Middle East, and the Gulf States. This geographic and scientific connectivity provides AcuraStem with additional opportunities for collaboration, clinical development, and long‑term growth beyond the EU, further strengthening the company’s global development strategy.
Europe is home to some of the world’s most deeply phenotyped ALS patient cohorts and highly coordinated clinical research networks, and AcuraStem’s clinical strategy reflects this strength. Establishing a permanent presence in Cyprus positions the company to participate directly in Europe’s growing investment in RNA‑based therapeutics and neurodegenerative disease research while operating within the EU regulatory framework.
“AcuraStem’s science and clinical vision have long been closely connected to Europe through our academic collaborators and clinical investigators,” said Sam Alworth, co‑founder and CEO of AcuraStem. “Establishing AcuraStem P2 Ltd formalizes that commitment, expands our ability to collaborate across Europe and neighboring regions, and provides essential infrastructure as we prepare to advance AS‑241 into the clinic.”
About AcuraStem
AcuraStem is a patient‑based biotechnology company pioneering broadly acting treatments for neurodegenerative diseases including sporadic ALS and frontotemporal dementia (FTD). AcuraStem’s iNeuroRx® platform enables the discovery and development of disease‑modifying therapies based on human patient biology. AcuraStem’s research is supported by grants and partnerships from leading public and private organizations focused on accelerating transformative therapies for patients.